These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ogawara K; Kuwabara S; Mori M; Hattori T; Koga M; Yuki N Ann Neurol; 2000 Oct; 48(4):624-31. PubMed ID: 11026446 [TBL] [Abstract][Full Text] [Related]
4. Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside. Yuki N; Ang CW; Koga M; Jacobs BC; van Doorn PA; Hirata K; van der Meché FG Ann Neurol; 2000 Mar; 47(3):314-21. PubMed ID: 10716250 [TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of Guillain-Barré and Miller Fisher syndromes subsequent to Campylobacter jejuni enteritis. Yuki N Jpn J Infect Dis; 1999 Jun; 52(3):99-105. PubMed ID: 10507987 [TBL] [Abstract][Full Text] [Related]
6. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barré syndrome. Koga M; Takahashi M; Masuda M; Hirata K; Yuki N Neurology; 2005 Nov; 65(9):1376-81. PubMed ID: 16162859 [TBL] [Abstract][Full Text] [Related]
7. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Jacobs BC; van Doorn PA; Schmitz PI; Tio-Gillen AP; Herbrink P; Visser LH; Hooijkass H; van der Meché FG Ann Neurol; 1996 Aug; 40(2):181-7. PubMed ID: 8773599 [TBL] [Abstract][Full Text] [Related]
8. [Pathogenesis of axonal Guillain-Barré syndrome]. Yuki N Rinsho Shinkeigaku; 2007 Jan; 47(1):1-7. PubMed ID: 17491330 [TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of bacterial risk factors for the development of Guillain-Barre syndrome after Campylobacter jejuni enteritis. ; ; . PubMed ID: 16425134 [TBL] [Abstract][Full Text] [Related]